

Guidelines for the Number of Embryos to Transfer Following In Vitro Fertilization

This guideline was reviewed by the Reproductive Endocrinology and Infertility Committee and the Maternal-Fetal Medicine Committee and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada and the Board of the Canadian Fertility and Andrology Society.

PRINCIPAL AUTHORS

Jason K. Min, MD, FRCSC, Ottawa ON

Paul Claman, MD, FRCSC, Ottawa ON

Ed Hughes, MB, ChB, MSc, FRCSC, Hamilton ON

REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY COMMITTEE

Anthony P. Cheung, MBBS, MPH, MBA, FRACOG, FRCSC, Vancouver BC

Paul Claman (Chair), MD, FRCSC, Ottawa ON

Margo Fluker, MD, FRCSC, Vancouver BC

Gwendolyn J. Goodrow, MD, FRCSC, Cambridge ON

James Graham, MD, FRCSC, Halifax NS

Gillian R. Graves, MD, FRCSC, Halifax NS

Louise Lapensée, MD, FRCSC, Outremont QC

Jason K. Min, MD, FRCSC, Ottawa ON

Sabrina Stewart, MD, FRCSC, Prince Albert SK

Susan Ward, RN, Hamilton ON

Benjamin Chee-Man Wong, MD, FRCSC, Calgary AB

MATERNAL-FETAL MEDICINE COMMITTEE

Anthony B. Armson, MD, FRCSC, Halifax NS

Marie-France Delisle, MD, FRCSC, Vancouver BC

Dan Farine (Chair), MD, FRCSC, Toronto ON

Robert Gagnon, MD, FRCSC, London ON

Lisa Keenan-Lindsay, RN, Toronto ON

Valerie Morin, MD, FRCSC, Cap-Rouge QC

William Mundle, MD, FRCSC, Windsor ON

Tracey Pressey, MD, FRCSC, Vancouver BC

Carol Schneider, MD, FRCSC, Winnipeg MB

John Van Aerde, MD, FRCPC, Edmonton AB

Key Words: Embryo transfer, in vitro fertilization, intracytoplasmic sperm injections, multiple pregnancy, multifetal gestation, assisted reproduction

Abstract

Objective: To review the effect of the number of embryos transferred on the outcome of in vitro fertilization (IVF), to provide guidelines on the number of embryos to transfer in IVF-embryo transfer (ET) in order to optimize healthy live births and minimize multiple pregnancies.

Options: Rates of live birth, clinical pregnancy, and multiple pregnancy or birth by number of embryos transferred are compared.

Outcomes: Clinical pregnancy, multiple pregnancy, and live birth rates.

Evidence: The Cochrane Library and MEDLINE were searched for English language articles from 1990 to April 2006. Search terms included embryo transfer (ET), assisted reproduction, in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), multiple pregnancy, and multiple gestation. Additional references were identified through hand searches of bibliographies of identified articles.

Values: Available evidence was reviewed by the Reproductive Endocrinology and Infertility Committee and the Maternal-Fetal Medicine Committee of the Society of Obstetricians and Gynaecologists of Canada and the Board of the Canadian Fertility and Andrology Society, and was qualified using the Evaluation of Evidence Guidelines developed by the Canadian Task Force on the Periodic Health Exam.

Benefits, Harms, and Costs: This guideline is intended to minimize the occurrence of multifetal gestation, particularly high-order multiples (HOM), while maintaining acceptable overall pregnancy and live birth rates following IVF-ET.

Recommendations

The recommendations made in this guideline were derived mainly from studies of cleavage stage embryos—those cultured for two or three days.

1. Individual IVF-ET programs should evaluate their own data to identify patient-specific, embryo-specific, and cycle-specific determinants of implantation and live birth in order to develop embryo transfer policies that minimize the occurrence of multifetal gestation while maintaining acceptable overall pregnancy and live birth rates. (III-B)
2. In general, consideration should be given to the transfer of fewer blastocyst stage embryos than cleavage stage embryos, particularly in women with excellent prognoses and high-quality blastocysts. (I-A)

Summary Statement

The following recommendations are generally intended for cleavage stage embryos transferred on day two or three. Because

This guideline reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.

Table 1. Criteria for quality of evidence assessment and classification of recommendations

Level of evidence*	Classification of recommendations†
I: Evidence obtained from at least one properly designed randomized controlled trial.	A. There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination.
II-1: Evidence from well-designed controlled trials without randomization.	B. There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination.
II-2: Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group.	C. There is poor evidence regarding the inclusion or exclusion of the condition in a periodic health examination.
II-3: Evidence from comparisons between times or places with or without the intervention. Dramatic results from uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category.	D. There is fair evidence to support the recommendation that the condition not be considered in a periodic health examination.
III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.	E. There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.

*The quality of evidence reported in these guidelines has been adapted from the Evaluation of Evidence criteria described in the Canadian Task Force on the Periodic Health Exam.⁵⁵

†Recommendations included in these guidelines have been adapted from the Classification of Recommendations criteria described in the Canadian Task Force on the Periodic Health Exam.⁵⁵

blastocyst stage embryos have higher implantation rates than cleavage stage embryos, fewer blastocyst stage embryos may need to be transferred. (II)

Recommendations (continued)

- In women under the age of 35 years, no more than two embryos should be transferred in a fresh IVF-ET cycle. (II-2A)
- In women under the age of 35 years with excellent prognoses, the transfer of a single embryo should be considered. Women with excellent prognoses include those undergoing their first or second IVF-ET cycle or one immediately following a successful IVF-ET cycle, with at least two high-quality embryos available for transfer. (I-A)
- In women aged 35 to 37 years, no more than three embryos should be transferred in a fresh IVF-ET cycle. In those with high-quality embryos and favourable prognoses, consideration should be given to the transfer of one or two embryos in the first or second cycle. (II-2A)
- In women aged 38 to 39 years, no more than three embryos should be transferred in a fresh IVF-ET cycle. (III-B) In those with high-quality embryos and favourable prognoses, consideration should be given to the transfer of two embryos in the first or second cycle. (III-B)
- In women over the age of 39 years, no more than four embryos should be transferred in a fresh IVF-ET cycle. (III-B) In those older women with high-quality embryos in excess of the number to be transferred, consideration should be given to the transfer of three embryos in the first IVF-ET cycle. (III-B)
- In exceptional cases when women with poor prognoses have had multiple failed fresh IVF-ET cycles, consideration may be given to the transfer of more embryos than recommended above in subsequent fresh IVF-ET cycles. (III-C)
- In donor–recipient cycles, the age of the oocyte/embryo donor should be used when determining the number of embryos to transfer. (II-2B)
- In women with obstetrical or medical contraindication to multifetal gestation, fewer embryos should be transferred to minimize the chance of multifetal gestation. In such cases, pre-treatment consultation with a maternal-fetal medicine specialist should be

pursued. (III-C) Whenever reasonable, consideration should be given to the transfer of a single embryo. (II-3B)

- Couples should be adequately counselled regarding the obstetrical, perinatal, and neonatal risks of multifetal gestation to facilitate informed decision making regarding the number of embryos to transfer. (II-3B) Emphasis on healthy singleton live birth as the measure of success in IVF-ET may be beneficial in promoting a reduction in the number of embryos transferred. (III-C)
- A strategy for public funding of IVF-ET must be developed for the effective implementation of guidelines limiting the number of embryos transferred. In the context of this strategy, total health care costs would be lower as a result of reductions in the incidence of multifetal pregnancies and births. (III-C)
- Efforts should be made to limit iatrogenic multiple pregnancies resulting from non-IVF-ET ovarian stimulation through the development of suitable guidelines for cycle cancellation and the removal of financial barriers to IVF-ET. (III-B)

Validation: This guideline was reviewed by the Reproductive Endocrinology and Infertility Committee and the Maternal-Fetal Medicine Committee and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada and the Board of the Canadian Fertility and Andrology Society.

Sponsor: Society of Obstetricians and Gynaecologists of Canada.

The quality of evidence reported in this document has been described using the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Periodic Health Exam (Table 1).

J Obstet Gynaecol Can 2006;28 (9)799–813

INTRODUCTION

In Canada, 1645 deliveries resulted from embryo transfer following in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) in 2001.¹ Of these, 31.5% were multiple births. Data from the Canadian Fertility and Andrology Society (CFAS) show that the incidence of multiple deliveries after IVF-embryo transfer (ET) had

Table 2. IVF-ET Births

Region	No. deliveries	Singletons (%)	Twins (%)	Triplets/+ (%)
Canada, 2003 ^{2*}	1780	69.0	29.4	1.6
Europe, 2002 ^{3†}	42827	75.5	23.2	1.3
USA, 2003 ^{4†}	25775	65.8	31.0	3.2

* all embryo transfers

† fresh, non-donor embryo transfers

Table 3. Canadian 2001 IVF-ET birth outcomes¹

Plurality	Number of neonates	Perinatal mortality rate	Mean GA at delivery (weeks)	Preterm birth	Very preterm birth	Low birth weight	Extremely low birth weight
Single	1141	2.3	39	15.7%	5.4%	10.4%	1%
Twin	958	3.7	36	65.5%	28.6%	52.7%	3.5%
Triplet	132	6.8	33	97.6%	6.7%	94.3%	16.4%
Quad	16	18.8	32	100%	100%	100%	0%

Perinatal mortality rate (per 1000 births); GA, Gestational age; preterm birth: < 37 weeks; very preterm birth: < 34 weeks; low birth weight: < 2500 g; extremely low birth weight: < 1000 g.

remained unchanged to 2003.² The incidence of multiple delivery after IVF-ET in Canada was closer to that of the United States (34.2%) than to the incidence in Europe (24.5%)^{3,4} (Table 2). The proportion of multifetal gestations attributed to IVF-ET is higher than after spontaneous conception. In the United States, IVF-ET contributed to 1.1% of all infants born in 2002 but accounted for 17.1% of all multiple births and 43.8% of high-order (triplet or more) deliveries.⁵ The incidence of twin and high-order multiple (HOM) births after IVF-ET was 14-fold and 54-fold greater than after spontaneous conception, respectively.⁶

It is well established that multifetal gestations are associated with a significantly greater incidence of complications than singleton gestations; most of these complications are directly related to increased rates of prematurity.^{7–11} More than 50% of twins and 90% of triplets are born preterm (< 37 weeks' gestation) and low birth weight (< 2500 g).¹² Compared with singletons, twins are born an average of three weeks earlier and 1000 g lighter, and triplets are born more than six weeks earlier and weigh 1600 g less.¹² The rates of very preterm and very low birth weight infants are disproportionately higher in multiples, and perinatal mortality increases with increasing plurality of birth^{1,5,13,14} (Table 3).

Twin gestations are associated with increased rates of maternal morbidity, including hypertensive disorders,^{15,16} Caesarean section,^{16–20} and postpartum hemorrhage,¹⁵ resulting in increased sick leave and antepartum

hospitalization.^{15,17} Even after adjustment for prematurity, twin neonates are more often admitted to NICU and require longer stays.^{19,21} They also suffer from increased rates of congenital malformations,^{11,19,22} some cognitive development difficulties,^{22–24} childhood hospitalization, and surgeries.^{25,26} Unlike in spontaneous cohorts, the increased incidence of cerebral palsy has not been consistently found with IVF-ET twin deliveries.^{27,28} Finally, IVF-ET multiple births may be associated with increased parental stress, marital discord, and financial hardship in comparison with singleton births.^{23,29–34}

Although there have been reductions in the incidence of high-order multiples with IVF-ET, twin delivery rates have remained unchanged.^{3,5} In Canada in 2001, almost one half of all children born after IVF-ET were from multifetal gestations, 86.6% of which were twins¹ (Table 3). Although it is recognized that twin gestations suffer increased rates of adverse neonatal and maternal outcomes when compared with singletons, there is still some debate among IVF-ET practitioners regarding the need to limit iatrogenic twin pregnancy.^{7,35–40} Given that twins are by far the most common multiple after IVF-ET, the bulk of excess morbidity and mortality attributable to IVF-ET conceptions occur in twin gestations.^{11,41–43} Furthermore, there is recent evidence that IVF-ET births associated with vanishing fetuses are at increased risk for perinatal and long-term neurological morbidity.^{44–49}

The excess occurrence of multifetal gestation following IVF-ET has resulted directly from the replacement of multiple embryos per transfer.^{1,3,5} According to an analysis of United States registry data from 1996 to 2002, there has been a decrease in the transfer of three or more embryos with a corresponding increase in double embryo transfer (DET). Over the same period, the overall pregnancy rate has increased from 33.7 to 42.2%, owing to an improvement in embryo implantation rates. Unfortunately, in most age groups, the multiple gestation rates after DET in 2002 were comparable with those following triple embryo transfer (TET) in 1996. Consequently, while there has been a decline in high-order multiples, the proportion of multiple pregnancies has actually increased from 46.5 to 49.9% because of a concurrent increase in twins.⁴³ In the United States in 2003, three or more embryos were transferred in 56.2% of fresh cycles.⁵ In Canada in 2001, at least three embryos were transferred in 50.6% of fresh IVF-ET cycles.¹ However, by 2004, only one or two embryos were transferred in 66% of cycles.²

Multifetal reduction can be used to decrease the occurrence of HOM delivery; however, reduction of twins to a singleton is generally not performed. The risk of pregnancy loss after reduction performed in experienced centres ranges from 4.5% to 15.4%.⁵⁰ Moreover, morbidity may be higher for twins resulting from multifetal reduction than for non-reduced twins.⁵¹⁻⁵³ Psychologically, elective reduction is often difficult for couples who have achieved pregnancy after a long duration of infertility. For some, the process can be highly stressful, and long-term guilt may follow.⁵⁴ For others, reduction may not be an option for ethical or religious reasons. Furthermore, the need for travel to centres with expertise in reduction can result in additional burdens for the couple. Ideally, primary prevention of HOM pregnancy is preferable, and the need for multifetal reduction should be minimized.

This guideline reviews available data on pregnancy, live birth, and multiple pregnancy and birth rates following fresh embryo transfer after conventional IVF/ICSI. Recommendations regarding the number of embryos to transfer are presented with the principal aim of reducing the occurrence of multifetal gestation while maintaining acceptable clinical pregnancy and live birth rates. These recommendations are not specifically applicable to frozen-thawed embryo transfer cycles, or to embryos derived from previously cryopreserved or in vitro-matured oocytes.

The quality of evidence reported in this guideline has been described using the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Periodic Health Exam (Table 1).⁵⁵

LIMITING THE NUMBER OF EMBRYOS TO TRANSFER IN IVF-ET

The existing literature on the number of embryos to transfer in IVF-ET is difficult to translate into strict guidelines. There are few randomized controlled trials providing robust evidence. Conclusions are difficult to draw from observational studies given that comparison groups generally differ in prognosis and are often not contemporary. Furthermore, comparisons among studies are confounded by heterogeneous methodology, insufficient reporting of key prognostic variables, and differences in baseline performance of individual IVF-ET programs. Finally, improvements in implantation rates over time often render all but the most current studies outdated.

Nevertheless, several observational studies have identified threshold values for the number of embryos transferred, above which pregnancy and live birth rates do not increase, although multiple pregnancy rates do.⁵⁶⁻⁵⁹ Furthermore, many programs have reported maintenance of pregnancy and birth rates with reductions in multiple and HOM rates when decreasing the number of embryos routinely transferred, particularly in young patients with favourable prognoses.⁶⁰⁻⁶⁴

Although the most effective strategy to reduce the incidence of IVF-ET multiples is to limit the number of embryos transferred per attempt, indiscriminate application of such policies would unnecessarily reduce the chance of pregnancy for many couples. Instead, decisions limiting the number of embryos transferred should be made according to the relevant probabilities of pregnancy and multifetal gestation.^{65,66} Several studies have characterized determinants of pregnancy and embryo implantation potential,^{59,67-71} and others have generated prediction models to minimize HOM and twin gestations.⁷²⁻⁷⁴

However, it is difficult and not always appropriate to generalize the results of individual studies to IVF-ET programs with heterogeneous patient populations and embryo implantation rates. Furthermore, there is currently no consensus regarding acceptable rates of twin and HOM gestations after IVF-ET. The determination of acceptable Canadian rates should be a priority for researchers and practitioners in reproductive medicine, as well as other stakeholders. In the absence of such consensus targets, and with recognition of the varying performance of individual IVF-ET programs, the following recommendations have been made based upon the existing, worldwide published literature. Given the rapidity of advances in IVF-ET,⁴³ it must be acknowledged that these recommendations will require regular revision to accurately reflect ongoing improvements in implantation rates.

Recommendation

1. Individual IVF-ET programs should evaluate their own data to identify patient-specific, embryo-specific, and cycle-specific determinants of implantation and live birth, in order to develop embryo transfer policies that minimize the occurrence of multifetal gestation while maintaining acceptable overall pregnancy and live birth rates. (III-B)

Cleavage Stage Versus Blastocyst Stage Embryos

The recommendations made in this guideline were derived mainly from studies of cleavage stage embryos—those cultured for two or three days. Although a recent meta-analysis did not demonstrate a difference in live birth and multiple pregnancy rates between the transfer of cleavage stage embryos and blastocyst embryos cultured for five or six days,⁷⁵ several studies have shown higher implantation rates following blastocyst culture, particularly for high-quality blastocysts.^{68,76–81} A recently published randomized controlled trial of elective single embryo transfer in young women with good prognosis demonstrated a significant improvement in live birth rate following blastocyst compared with cleavage stage transfer.⁸² Consequently, consideration should be given to the transfer of fewer blastocyst stage embryos than of comparable quality cleavage stage embryos.

Recommendation

2. In general, consideration should be given to the transfer of fewer blastocyst stage embryos than cleavage stage embryos, particularly in women with excellent prognoses and high-quality blastocysts. (I-A)

WOMEN UNDER THE AGE OF 35 YEARS

A small ($n = 56$) randomized controlled trial published more than 10 years ago compared DET with transfer of four embryos (QET) in good prognosis patients under the age of 35 years. DET resulted in lower live birth (28.6% vs. 53.6%) and multiple pregnancy rates (10.7% vs. 21.4%). HOM pregnancies did not result from DET, and four of five multiples after QET were triplet.⁸³ A more recent randomized controlled trial comparing DET with TET in 212 women found the live delivery rate was similar for DET and TET (30.1% vs. 24.5%), and multiple (15.0% vs. 41.4%, $P < 0.05$) and HOM pregnancies (0% vs. 6.9%) were substantially decreased for DET compared with TET.⁸⁴

Several observational studies have reported comparable pregnancy rates, with an accompanying maintenance or reduction in multiples, for DET compared with TET in young women with good prognoses. Although a significant incidence of HOM was reported after TET in all studies (3.9–18.0%), none resulted from DET in these series.^{85–89}

In women with lower quality embryos but otherwise similar prognoses, TET has resulted in higher pregnancy rates than DET; however, rates were not as high as with DET of good embryos.^{86,87,89} Although TET in women with lower quality embryos resulted in multiple rates similar to DET in women with good embryos, HOM rates were still higher after TET.^{86,89} Compared with DET in good prognosis patients, TET in patients with poorer prognoses resulted in similar or lower pregnancy rates, with increased multiple and HOM rates.^{90,91}

Based upon 44 236 cycles performed in the United Kingdom from 1991 to 1995, when the legislated maximum number of embryos transferred was three, Templeton and Morris generated estimates for live birth and multiple birth rates standardized for nulliparous women with tubal infertility and one to three prior IVF attempts. In women aged 30 years with greater than four fertilized eggs, DET resulted in the same live birth rate as TET (21.3% vs. 21.1%) with a significantly lower multiple birth rate (28.6% vs. 39.4%, $P < 0.001$). Similar findings were reported in women with only three or four fertilized eggs.⁵⁹

Schieve et al.⁹² reported a retrospective analysis of 35 554 fresh, non-donor embryo transfers performed in the United States in 1996. Unlike in the United Kingdom, there was no legislated maximum number of embryos permitted for transfer. In women aged 30 to 34 years, there were significant increases in both live birth rates (35.1% vs. 19.4%, $P < 0.01$) and multiple birth rates (39.8% vs. 19.7%, $P < 0.01$) after TET compared with DET, and the transfer of four or more embryos resulted in increased multiple births, particularly high order (6.7%), without substantial improvement in live birth rates. Similar findings were noted in women aged 20 to 29 years.⁹² Reflecting significant improvement in embryo implantation rates, analysis of 2002 United States registry data found that in unmatched women aged under 35 years, DET gave similar live birth rates to TET (46.3% vs. 43.7%) with lower multiple (36.1% vs. 42.3%) and HOM (0.8% vs. 7.2%) rates.⁵

SUMMARY STATEMENT

The following recommendations are generally intended for cleavage stage embryos transferred on day two or three. Because blastocyst stage embryos have higher implantation rates than cleavage stage embryos, fewer blastocyst stage embryos may need to be transferred. (II)

Recommendation

3. In women under the age of 35 years, no more than two embryos should be transferred in a fresh IVF-ET cycle. (II-2A)

Table 4. eSET versus DET: randomized controlled trials

Trial	n	Ongoing Pregnancy* / Live Birth [†]		Multiples	
		eSET %	DET %	eSET %	DET %
Gerris 1999 ⁹⁴	53	38.5 (10/26)	74.1 (20/27)	10 (1/10)	30.0 (6/20)
Martikainen 2001 ⁹⁶	144	29.7 (22/74)	40.0 (28/70)	4.5 (1/22)	39.3 (11/28)
Gardner 2004 ⁹³	48	60.9 (14/23)	76.0 (19/25)	0 (0/14)	47.4 (9/19)
Thurin 2004 ^{97‡}	634	29.6 (91/307)	43.4 (142/327)	1.1 (1/91)	33.1 (47/142)
Lukassen 2005 ^{95§}	107	25.9 (14/54)	35.8 (19/53)	0 (0/14)	36.8 (7/19)
van Montfoort 2005 ⁹⁸	308	21.4 (33/154)	40.3 (62/154)	0 (0/33)	21.0 (13/62)
Total	1294	28.8 (184/638)	44.2 (290/656)	1.6 (3/184)	32.1 (93/290)

n: number; eSET: elective single embryo transfer; DET: double embryo transfer.

* Ongoing pregnancy rate per transfer: Gerris 1999 (> 12 weeks), Gardner 2004 (> 6.5 weeks), and van Montfoort (> 7 weeks).

[†] Live birth rate per transfer: Martikainen 2001, Thurin 2004, and Lukassen 2005.

[‡] per protocol analysis

[§] First fresh eSET cycle only

^{||}Not significant

ELECTIVE SINGLE EMBRYO TRANSFER

To date, six randomized controlled trials have compared pregnancy, live birth, and multiple rates following DET with those following elective single embryo transfer (eSET)^{93–98} (Table 4). When at least two embryos were available for transfer in fresh IVF-ET cycles, DET resulted in a higher pregnancy or live birth rate than eSET. Although some studies failed to demonstrate a statistically significant difference,^{93,95,96} a systematic review of four of these trials confirmed that DET resulted in significantly higher clinical pregnancy rates (odds ratio [OR] 2.16; 95% confidence interval [CI], 1.65–2.82) and live birth rates (OR 1.94; 95% CI 1.46–2.55) per woman than eSET.⁹⁹ Multiple pregnancy rates were also significantly increased with DET (OR 23.55; 95% CI, 8.00–69.29).⁹⁹ Elective eSET was effective in preventing HOM and reducing the incidence of twins to that of monozygotic twinning associated with IVF-ET.^{100,101} There was a 1.6% rate of twins in the eSET groups, and 2.2% of multiples in the DET groups were triplets (Table 4).

Participation in four of the six eSET randomized controlled trials was restricted to patients with optimal prognosis (Table 5). In the five trials that provided demographic data, participants on average were aged under 34 years and undergoing their first or second IVF-ET attempt. The mean number of oocytes retrieved was greater than nine, with a high number of embryos available for transfer.^{93,95–98} In the Martikainen et al. trial, older age was not a specific exclusion criteria for 70% of participants, however the mean age of participants was 31 years.⁹⁶ The van Montfoort et al. trial was specifically conducted in a population with a

more heterogeneous prognosis. Although the participants were also young (mean age 32.5), only 42% had at least one good quality embryo available for transfer. The ongoing pregnancy rate was twice as high after DET than after eSET (40.2% vs. 21.4%, $P < 0.05$).⁹⁸ Moreover, the ongoing pregnancy rate in the eSET group was the lowest of all randomized controlled eSET trials (Table 4).

Several observational studies have also reported the efficacy of eSET in minimizing twin gestations (Table 6). Unlike the randomized trials, the majority of these studies found similar clinical pregnancy rates after eSET and DET, likely reflecting the heterogeneity in embryo quality and patient prognosis in the DET groups.^{91,102–112} Analysis of the 2002 US registry data supports the application of eSET in good-prognosis patients. In women aged under 35 years with excess embryos “set aside for future use,” eSET resulted in a 47.4% live birth rate per transfer with no multiples. DET was associated with a higher live birth rate (51.8%) but high twin (38.8%) and HOM birth rates (0.9%).⁵

Cumulative rates including contributions of cryopreserved embryos

In the largest eSET randomized controlled trial published by Thurin et al., women in the eSET group who did not achieve a live birth after the fresh embryo transfer were subsequently eligible for the transfer of a single frozen-thawed embryo.⁹⁷ The per protocol analysis demonstrated an insignificantly lower cumulative live birth rate with the eSET strategy than in the fresh DET group (38.8% vs. 43.4%),

Table 5. Eligibility criteria for eSET trials

Trial	Patient	Attempt No.	Embryos
Gerris 1999 ⁹⁴	Age < 34 y	1st	≥ 2 available; 4 or 5 cells on day 2 and ≥ 7 cells on day 3, no multinucleation and < 20% fragmentation
Martikainen 2001 ⁹⁶	Age < 36 y in 43 of 144, no age criteria in 101 of 144	1st in 43, 1st or 2nd in 101	≥ 4 available; even-sized blastomeres and < 20% fragmentation on day 2
Gardner 2004 ⁹³	FSH ≤ 10 IU/L, E ₂ < 80 pg/mL, normal cavity, ≥ 10 follicles > 12mm at hCG	Not specified	≥ 2 available; blastocysts
Thurin 2004 ⁹⁷	Age < 36 y (< 35 for initial recruitment)	1st or 2nd	≥ 2 available; < 20% fragmentation and 4-6 cells on day 2 or 6-10 cells on day 3 or expanded blastocysts on day 5/6 (≥ 3 for initial recruitment period)
Lukassen 2005 ⁹⁵	Age < 35 y, FSH ≤ 10 IU/L	1st	≥ 2 available; < 10% fragmentation
van Montfoort 2005 ⁹⁸	Any	1st	≥ 2 normally fertilized embryos

eSET: elective single embryo transfer; FSH: follicle stimulating hormone; E₂: estradiol; hCG: human chorionic gonadotropin

while maintaining a significant reduction in multiple rates (0.8% vs. 33.1%, $P < 0.001$).⁹⁷ A few cohort studies have also demonstrated the benefit of cryo-augmentation. With the inclusion of pregnancies from frozen-thawed embryos, pregnancy rates per woman following eSET were similar to those after fresh DET, with minimal increases in multiple pregnancies resulting from the transfer of more than one frozen-thawed embryo.^{102,103,111–113}

It is noteworthy that 17% of women eligible for frozen-thawed embryo transfer in the Thurin et al. trial⁹⁷ did not receive a transfer because cryopreserved embryos did not survive the thaw. It is likely that at least a portion of these women would have achieved a pregnancy if they had received a fresh DET.¹¹⁴ This suggests that assessment of a clinic's embryo cryopreservation program is important when contemplating eSET.^{93,102,115,116}

Estimated Impact of eSET

It was estimated that application of eSET in 25% to 30% of all IVF-ET cycles in Europe would result in a reduction of multiple births from 25–50% to 12–15%.³⁵ However, the 2002 European registry data suggest eSET has yet to have significant impact.³ A few programs with young patient populations have reported a significant uptake of eSET (41–65%). These European programs have demonstrated that multiple pregnancy rates can be minimized (7–11%) while maintaining acceptable clinical pregnancy rates (29–42%).^{101,117–120} Finland remains the only nation to demonstrate a reduction in multiple birth in IVF-ET.¹¹⁷ It has been estimated that about 30% of IVF-ET cycles performed in the United States are in young, good-prognosis patients who would be eligible for eSET.¹¹⁴

Recommendation

4. In women under the age of 35 years with excellent prognoses, the transfer of a single embryo should be considered. Women with excellent prognoses include those undergoing their first or second IVF-ET cycle or one immediately following a successful IVF-ET cycle, with at least two high-quality embryos available for transfer. (I-A)

WOMEN AGED 35 TO 39 YEARS

Schieve et al. published an analysis of 1996 IVF-ET registry data from the United States.⁹² Among women aged 35 to 39 years, live birth rates increased with the transfer of increasing numbers of embryos, peaking at four. Transfer of four embryos (QET) resulted in a higher live birth rate than TET (33.3% vs. 23.0%, $P < 0.01$). Multiple birth rates (37.5% vs. 29.4%, $P < 0.01$) and HOM birth rates (5.4% vs. 2.2%, $P < 0.01$) were also higher after QET than after TET. Although DET decreased the occurrence of multiple births (11.6%) and eliminated HOM births, the decrease in the live birth rate was substantial (14.0%).⁹²

In 1222 unmatched transfer cycles, Svendsen et al. in 1996 found non-significant increases in ongoing and multiple pregnancy rates with up to four embryos transferred.¹²¹ Clinical pregnancy and multiple pregnancy rates with QET were 23.4% and 24.2% respectively. A similar proportion of HOM pregnancies occurred following TET (3.2%) and QET (3.9%), and none followed DET.¹²¹ Hu et al. in 1998 reported a similar analysis of 224 unmatched transfers of up to five embryos.¹²² With poor quality embryos, pregnancy

Table 6. Elective single versus double embryo transfers: observational studies

Study	Pregnancy Rate*		Multiples†	
	eSET %	DET %	eSET %	DET %
Vilksa 1999 ¹⁰²	29.7 (22/74)	29.4 (218/742)	0 (0/22)	23.9 (52/218)
Catt 2003 ¹⁰³	44.1 [‡] (49/111)	58.8 [‡] (161/274)	2.0 (1/49)	44.1 (71/161)
Gerris 2002 ⁹¹	35.1 (105/299)	36.2 (309/853)	1.0 (1/105)	35.3 (109/309)
De Sutter 2003 ¹⁰⁴	28.2 (163/579)	32.7 (734/2319)	0.7 (1/163)	30.4 (223/734)
Kovacs 2003 ¹⁰⁵	31.8 (54/170)	33.5 (816/2436)	0 (0/54)	33.1 (244/737) [§]
Soderstrom-Anttila 2003 ¹⁰⁶	40.8 (20/49)	41.0 (32/78)	0 (0/20)	36.0 (9/35)
Tiitinen 2003 ¹⁰⁷	34.5 (162/470)	36.7 (376/1024)	1.2 (2/162)	30.1 (113/376)
Gerris 2004 ¹⁰⁸	40.3 (83/206)	40.4 (65/161)	0 (0/83)	30.8 (20/65)
Martikainen 2004 ¹⁰⁹	34.7 (107/308)	31.8 (255/803)	0.9 (1/107)	na
Criniti 2005 ¹¹¹	75.6 (31/41)	78.8 (52/66)	3.2 (1/31)	61.5 (32/52)
Henman 2005 ¹¹²	44.6 [‡] (54/121)	57.9 [‡] (163/285)	1.9 (1/54)	44.2 (72/163)
van Montfoort 2005 ¹¹⁰	31.6 (35/111)	29.0 (119/410)	0 (0/35)	33.6 (40/119)
Total	34.9 (885/2539)	34.9 (3300/9451)	0.9 (8/885)	33.2 (985/2969)

eSET: elective single embryo transfer; DET: double embryo transfer.
* per transfer
† all comparisons statistically significant
‡ $P < 0.05$
§ data available for 737 of 816 cases

rates increased after QET. With fair quality embryos, pregnancy rates did not increase after TET. With good quality embryos, transfer of five embryos (5ET) resulted in the highest pregnancy rate, but the HOM rate was significant at 40%. In this subgroup, HOM appeared with the transfer of three or more embryos. When only fair quality embryos were transferred, HOM pregnancies were first noted with QET, and when poor quality embryos were transferred, HOM pregnancies were first noted with 5ET.¹²²

In a review of 138 unmatched transfers in women aged 35 to 39 years, Giannini et al. in 2004 found TET resulted in a higher clinical pregnancy rate (42.0% vs. 34.2%) than DET, but a similar multiple pregnancy rate (16.7% vs. 15.4%).¹²³ In 814 fresh and frozen transfers in women aged 37 years and over, Elsner et al. in 1997 reported increasing live birth rates with the transfer of greater numbers of embryos up to three.⁵⁷ TET resulted in significantly higher live birth rates than DET (34.5% vs. 16.0%, $P < 0.05$). However, multiple pregnancy (29.1% vs. 8.0%, $P < 0.05$) and HOM (1.3% vs. 0%) rates were also higher after TET.⁵⁷ Similarly, Salha et al. in 2000 published outcomes of women aged over 35 years undergoing their first cycle with at least six embryos available for transfer.⁸⁶ In 95 women with three good quality embryos remaining after transfer, TET

compared with DET resulted in higher clinical pregnancy rates (37.7% vs. 20.0%, $P < 0.05$) and higher live birth rates (30.6% vs. 20.0%, $P < 0.05$). Twin birth rates were similar (3.8% vs. 0%) and there were no HOM in either group.⁸⁶ Matson et al. in 1999 reported similar clinical pregnancy rates in 355 cycles after DET (24%) and TET (20%), without significant difference in multiple gestations.⁸⁸

Based on data from the 1996 United Kingdom registry, Templeton and Morris estimated that a woman aged 35 years with more than four fertilized eggs had the same probability of live birth after DET as after TET (17.0% vs. 16.9%); however, the risk of multiple birth was significantly reduced (25.6% vs. 32.6%, $P < 0.001$) after DET.⁵⁹ United States registry data from 2002 demonstrated that in women aged 35 to 37 years, live birth rates (39.7% vs. 37.7%) multiple birth rates (36.6% vs. 29.2%) and HOM birth rates (4.4% vs. 0.8%) were higher after TET than after DET.⁵ When limited to cycles with surplus embryos remaining after transfer, there was no benefit in live birth rate with TET over DET, and HOM rates remained higher after TET.⁵ However, in unselected women aged 38 to 40 years, live birth rates improved after TET compared with DET (28.9% vs. 23.3%), with a corresponding increase in multiple (24.3% vs. 18.8%) and HOM births (2.6% vs. 0%). In

those with excess embryos following transfer, the birth rate was highest after DET (43.1%).⁵

Although some eSET studies have included a few older women (typically under 38 years),^{101,103,110–112,119} the application of eSET in older women has not been extensively reported. In 862 women aged 35 to 39 years with at least four good quality embryos available for transfer, a 2003 study found that the clinical pregnancy rate after eSET was not significantly different from the rate after DET (26.7% vs. 30.5%).¹⁰⁵ Other observational studies have also reported similar pregnancy rates after eSET in small numbers of older women.^{107,113,117,124}

Recommendations

5. In women aged 35 to 37 years, no more than three embryos should be transferred in a fresh IVF-ET cycle. In those with high-quality embryos and favourable prognoses, consideration should be given to the transfer of one or two embryos in the first or second cycle. (II-2A)
6. In women aged 38 to 39 years, no more than three embryos should be transferred in a fresh IVF-ET cycle. (III-B) In those with high-quality embryos and favourable prognoses, consideration should be given to the transfer of two embryos in the first or second cycle. (III-B)

WOMEN AGED OVER 39 YEARS

Compared with younger women, women over 39 years have lower pregnancy, delivery, and multiple rates for any given number of embryos transferred.⁵ An unmatched retrospective review published in 1997 of 525 ICSI cycles in women over 39 years found that the transfer of four or more embryos resulted in significant improvement in the clinical pregnancy rate (20.4% vs. 10.0%, $P < 0.005$), and higher twin rates (17.2% vs. 11.1%) than the transfer of one to three embryos.¹²⁵ In an unmatched comparison of 320 embryo transfers, Svendsen et al. in 1996 found that TET in these older women resulted in a higher ongoing pregnancy rate than DET (14.4% vs. 3.2%), and HOM did not occur in this series.¹²¹

When the maximum number of embryos transferred was restricted to three, Templeton and Morris estimated that women aged 40 years with more than four fertilized eggs had the same probability of live birth (13.5% vs. 13.3%) and multiple birth (22.8% vs. 26.5%) after DET and TET, respectively. With only three or four fertilized eggs, TET improved the live birth rate without increasing multiples in this group of women.⁵⁹

In women aged 41 to 42 years using fresh embryos, the most recent unadjusted registry data from the United States showed increasing live birth and multiple birth rates with

the transfer of more embryos. In women receiving five or more embryos, live birth, multiple birth, and HOM birth rates were 21.8%, 22.1%, and 2.5%, respectively. The corresponding rates resulting from transfer of four embryos were 16.6%, 15.0%, and 0.9%, respectively.⁵ When restricted to women with excess embryos remaining after transfer, live birth rates were similar after transfer of two (27.9%) and five or more embryos (29.1%), but the transfer of five or more embryos compared with DET resulted in considerably higher rates of multiple birth (28.0% vs. 16.7%) and HOM birth (8.0% vs. 0%).⁵

Recommendation

7. In women over the age of 39 years, no more than four embryos should be transferred in a fresh IVF-ET cycle. (III-B) In those older women with high-quality embryos in excess of the number to be transferred, consideration should be given to the transfer of three embryos in the first IVF-ET cycle. (III-B)

POOR PROGNOSIS

In 1995, Azem et al. reported a significant improvement in pregnancy rates following the transfer of six or more embryos compared with five embryos in women with at least four prior failed IVF-ET attempts.¹²⁶ Aside from this single study, there is no published evidence demonstrating improvements in pregnancy or live birth rates after the transfer of more embryos in subsequent IVF-ET cycles than the number transferred in previous failed cycles. Nevertheless, the transfer of greater numbers of embryos in women with multiple fresh IVF-ET failures is not uncommon. This practice has also been extended to women predicted to have a poor probability of conception on the basis of other prognosticators such as embryo quality, also with little supportive evidence regarding efficacy.¹²² Although the preceding recommendations are not intended to be punitive for women with poorer prognoses for conception, caution and sound clinical judgement must be exercised when exceeding their prescribed maximums.

Recommendation

8. In exceptional cases when women with poor prognoses have had multiple failed fresh IVF-ET attempts, consideration may be given to the transfer of more embryos than recommended above in subsequent fresh IVF-ET cycles. (III-C)

DONOR-RECIPIENT CYCLES

Licciardi et al. reported a retrospective analysis of outcomes of 449 donor-recipient cycles.¹²⁷ With embryos derived from young donors (aged 21 to 30 years), DET versus TET resulted in similar clinical pregnancy (57.5% vs. 55.8%) and

multiple pregnancy (40.5% vs. 51.0%) rates. However, DET versus TET resulted in significantly lower HOM rates (0% vs. 13.7%, $P < 0.01$).¹²⁷ In another unmatched retrospective study, eSET of good quality embryos resulted in similar live birth rates to those achieved after DET of unknown quality embryos (32.6% vs. 32.1%), with a significant reduction in twins (0% vs. 36.0%, $P < 0.01$).¹⁰⁶ More recently, a small retrospective study reported a clinical pregnancy rate of 88% without any multiple gestations following single blastocyst transfer.¹¹¹

Recommendation

9. In donor–recipient cycles, the age of the oocyte/embryo donor should be used when determining the number of embryos to transfer. (II-2B)

MEDICAL SINGLE EMBRYO TRANSFER

In circumstances that make the avoidance of multifetal gestation more important than usual, it may be prudent to limit the number of embryos transferred, regardless of a possible reduction in the chance of achieving pregnancy. Obstetrical indications or medical conditions that may be exacerbated by multifetal gestation include severe maternal disease (e.g., diabetes mellitus, cardiovascular disease), morbid obesity, uterine malformation, history of cervical incompetence or hysterotomy, previous preterm delivery, indication for specific prenatal diagnosis, and risk of ovarian hyperstimulation syndrome.¹⁰¹ In a retrospective analysis, Vilska et al.¹⁰² reported outcomes following eSET in 74 women with contraindications to multifetal gestation. Compared with an unselected cohort receiving DET, the women receiving eSET had similar clinical pregnancy rates (29.7% vs. 29.4%) with a significant reduction in twins (0% vs. 23.9%).¹⁰² A similar pregnancy rate (30.6%) has been reported in a series of 72 women aged over 37 years receiving eSET for medical or obstetrical indications.¹¹⁷

Recommendation

10. In women with obstetrical or medical contraindication to multifetal gestation, fewer embryos should be transferred to minimize the chance of multifetal gestation. In such cases, pre-treatment consultation with a maternal-fetal medicine specialist should be pursued. (III-C) Whenever reasonable, consideration should be given to the transfer of a single embryo. (II-3B)

ATTITUDES TOWARDS MULTIFETAL GESTATION

Despite the significant body of evidence, many patients are unaware that twin pregnancies are associated with increased risks of adverse maternal and neonatal outcomes.^{32,35,128,129} For many patients suffering from long-term infertility, multiple birth is an acceptable and even desired outcome of

fertility treatment.^{95,128–132} Some data suggest that counseling regarding the risks of twins may be inadequate.¹³³ Consultation with a specialist in maternal-fetal medicine may be helpful in providing a more accurate understanding of the risks associated with multifetal gestations, particularly with higher order multiples. Murray et al. found that even when informed about these risks, although two thirds of couples would prefer singletons, less than 10% would be deterred by the prospect of twins.¹³² Emphasis on healthy singleton live birth rather than simply achieving pregnancy as a measure of success would be beneficial in promoting reductions in the numbers of embryos transferred.

Recommendation

11. Couples should be adequately counselled regarding the obstetrical, perinatal, and neonatal risks of multifetal gestation to facilitate informed decision making regarding the number of embryos to transfer. (II-3B) Emphasis on healthy singleton live birth as the measure of success in IVF-ET may be beneficial in promoting a reduction in the number of embryos transferred. (III-C)

ECONOMIC CONSIDERATIONS

Many patients and physicians are reluctant to reduce the number of embryos transferred for fear of a reduction in the probability of pregnancy.^{66,93–95,97,134} This is particularly relevant when patients assume the costs of IVF-ET treatments and may not be able to afford multiple attempts. In this context, respect for patient autonomy should be observed.¹³⁵

Studies in the United States have demonstrated reductions in the number of embryos transferred per attempt with subsequent decreases in multiple and HOM rates in jurisdictions providing insurance coverage for IVF.^{136,137} Surveys have also suggested that the uptake of eSET would increase with greater reimbursement of subsequent treatment attempts.^{129,132} In Belgium, limits on the number of embryos transferred per attempt, including eSET in good prognosis patients, have been legislated; however, these policies are appropriately tied to state reimbursement of IVF-ET costs.^{118,138,139}

Direct maternal and early neonatal costs are significantly elevated by plurality of birth.^{140,141} Although eSET results in a lower birth rate than DET,^{93–97} analyses including the costs of IVF treatment have shown the cost per baby born to be comparable after eSET and DET.^{95,108,141,142} When considering the long-term costs associated with higher morbidity in children born from multifetal gestations, public funding of IVF-ET may prove to be a cost-effective strategy through improved participation in eSET and other strategies to reduce the incidence of iatrogenic multiple pregnancy.

Recommendation

12. A strategy for public funding of IVF-ET must be developed for the effective implementation of guidelines limiting the number of embryos transferred. In the context of this strategy, total health care costs would be lower as a result of reductions in the incidence of multifetal pregnancies and births. (III-C)

NON-IVF-ET INFERTILITY TREATMENTS AND MULTIFETAL GESTATION

A significant proportion of multiple pregnancies and births are derived from non-IVF-ET fertility treatments, particularly superovulation. In 2000, 21% of twin and 40% of HOM births in the United States were attributed to ovarian stimulation without IVF-ET.⁶ Similar statistics have been reported from other jurisdictions.^{3,143} Although the efficacy of superovulation is significantly less than that of IVF-ET,¹⁴⁴ superovulation is also much less expensive, and it therefore remains a frequently employed treatment modality. Although control over the occurrence of multifetal, and especially HOM, gestations can be exercised through limits on the number of embryos transferred in IVF-ET, control over multiples from superovulation is not as simple to achieve.^{8,145}

In order to maximize any reduction in multifetal gestation resulting from infertility therapy, the contribution of non-IVF-ET fertility treatments should also be addressed. One strategy is the formulation of appropriate guidelines for the cancellation of superovulation cycles.¹⁴⁶ Another is to reduce the use of superovulation in favour of IVF-ET.¹⁴⁷ Removing the financial barriers to IVF-ET through public funding could reduce the incidence of iatrogenic multifetal gestation while increasing the overall efficacy infertility treatment.

Recommendation

13. Efforts should be made to limit iatrogenic multiple pregnancies resulting from non-IVF-ET ovarian stimulation, through the development of suitable guidelines for cycle cancellation and the removal of financial barriers to IVF-ET. (III-B)

SUMMARY

The desired outcome of infertility treatment is the birth of a healthy child. As multifetal gestations are associated with higher rates of morbidity and mortality, their disproportionately high occurrence after IVF-ET should be minimized. The transfer of fewer embryos per attempt should be employed as primary prevention. However, indiscriminate application of limitations upon the number of embryos transferred would be inappropriate until accurate predictors

of successful implantation can be determined. Decisions on the number of embryos to transfer should be based upon prognosis determined by variables including the woman's age, prior outcomes, and the number and quality of embryos available for transfer, and should be made to minimize the risk of multifetal gestation while maintaining a high probability of healthy live birth.

REFERENCES

1. Gunby J, Daya S. Assisted reproductive technologies (ART) in Canada: 2001 results from the Canadian ART Register. *Fertil Steril* 2005;84:590-9.
2. Canadian Fertility and Andrology Society. CFAS press release: Human assisted reproduction live birth rates for Canada. November 17, 2005. <http://www.cfas.ca/english/news/Nov17-2005.asp> Last updated November 17, 2005. Cited April 7, 2006.
3. Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. *Hum Reprod* 2006;21(7):1680-97.
4. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. 2003 Assisted Reproductive Technology Success Rates. Updated March 23, 2006. <http://www.cdc.gov/ART/ART2003/index.htm> Cited May 4, 2006.
5. Wright VC, Schieve LA, Reynolds MA, Jeng G. Assisted reproductive technology surveillance—United States, 2002. *MMWR Surveill Summ* 2005;54:1-24.
6. Reynolds MA, Schieve LA, Martin JA, Jeng G, Macaluso M. Trends in multiple births conceived using assisted reproductive technology, United States, 1997-2000. *Pediatrics* 2003;111:1159-62.
7. Multiple gestation pregnancy. The ESHRE Capri Workshop Group. *Hum Reprod* 2000;15:1856-64.
8. Multiple pregnancy associated with infertility therapy. *Fertil Steril* 2004;82 Suppl 1:S153-S157.
9. Adamson D, Baker V. Multiple births from assisted reproductive technologies: a challenge that must be met. *Fertil Steril* 2004;81:517-22.
10. Devine PC, Malone FD. Maternal complications associated with multiple pregnancy. *Clin Obstet Gynecol* 2004;47:227-36.
11. Pinborg A. IVF/ICSI twin pregnancies: risks and prevention. *Hum Reprod Update* 2005;11:575-93.
12. Alexander GR, Kogan M, Martin J, Papiernik E. What are the fetal growth patterns of singletons, twins, and triplets in the United States? *Clin Obstet Gynecol* 1998;41:114-25.
13. Blondel B, Kogan MD, Alexander GR, Dattani N, Kramer MS, Macfarlane A, et al. The impact of the increasing number of multiple births on the rates of preterm birth and low birthweight: an international study. *Am J Public Health* 2002;92:1323-30.
14. Alexander GR, Slay WM, Salihu H, Kirby RS. Fetal and neonatal mortality risks of multiple births. *Obstet Gynecol Clin North Am* 2005;32:1-16, vii.
15. Pinborg A, Loft A, Schmidt L, Langhoff-Roos J, Nyboe Andersen A. Maternal risks and perinatal outcome in a Danish national cohort of 1005 twin pregnancies: the role of in vitro fertilization. *Acta Obstet Gynecol Scand* 2004;83:75-84.
16. Koivurova S, Hartikainen AL, Karinen L, Gissler M, Hemminki E, Martikainen H, et al. The course of pregnancy and delivery and the use of maternal healthcare services after standard IVF in Northern Finland 1990-1995. *Hum Reprod* 2002;17:2897-903.
17. Klemetti R, Gissler M, Hemminki E. Comparison of perinatal health of children born from IVF in Finland in the early and late 1990s. *Hum Reprod* 2002;17:2192-8.
18. Dhont M, De Sutter P, Ruysinck G, Martens G, Bekaert A. Perinatal outcome of pregnancies after assisted reproduction: a case-control study. *Am J Obstet Gynecol* 1999;181:688-95.

19. Pinborg A, Loft A, Nyboe Andersen A. Neonatal outcome in a Danish national cohort of 8602 children born after in vitro fertilization or intracytoplasmic sperm injection: the role of twin pregnancy. *Acta Obstet Gynecol Scand* 2004;83:1071–8.
20. Westergaard HB, Johansen AM, Erb K, Andersen AN. Danish National In-Vitro Fertilization Registry 1994 and 1995: a controlled study of births, malformations and cytogenetic findings. *Hum Reprod* 1999;14:1896–902.
21. Dhont M, De Neubourg F, Van der Elst J, De Sutter P. Perinatal outcome of pregnancies after assisted reproduction: a case-control study. *J Assist Reprod Genet* 1997;14:575–80.
22. Bonduelle M, Liebaers I, Deketelaere V, Derde MP, Camus M, Devroey P, et al. Neonatal data on a cohort of 2889 infants born after ICSI (1991–1999) and of 2995 infants born after IVF (1983–1999). *Hum Reprod* 2002;17:671–94.
23. Pinborg A, Loft A, Schmidt L, Andersen AN. Morbidity in a Danish national cohort of 472 IVF/ICSI twins, 1132 non-IVF/ICSI twins and 634 IVF/ICSI singletons: health-related and social implications for the children and their families. *Hum Reprod* 2003;18:1234–43.
24. Mikkola K, Ritari N, Tommiska V, Salokorpi T, Lehtonen L, Tammela O, et al. Neurodevelopmental outcome at 5 years of age of a national cohort of extremely low birth weight infants who were born in 1996–1997. *Pediatrics* 2005;116:1391–400.
25. Ericson A, Nygren KG, Olausson PO, Kallen B. Hospital care utilization of infants born after IVF. *Hum Reprod* 2002;17:929–32.
26. Pinborg A, Loft A, Rasmussen S, Nyboe Andersen A. Hospital care utilization of IVF/ICSI twins followed until 2–7 years of age: a controlled Danish national cohort study. *Hum Reprod* 2004;19:2529–36.
27. Stromberg B, Dahlquist G, Ericson A, Finnstrom O, Koster M, Stjernqvist K. Neurological sequelae in children born after in-vitro fertilisation: a population-based study. *Lancet* 2002;359:461–5.
28. Pinborg A, Loft A, Schmidt L, Greisen G, Rasmussen S, Nyboe Andersen A. Neurological sequelae in twins born after assisted conception: controlled national cohort study. *BMJ* 2004;329:311.
29. Bryan E. The impact of multiple preterm births on the family. *BJOG* 2003;110 Suppl 20:24–8.
30. Ellison MA, Hall JE. Social stigma and compounded losses: quality-of-life issues for multiple-birth families. *Fertil Steril* 2003;80:405–14.
31. Ellison MA, Hotamisligil S, Lee H, Rich-Edwards JW, Pang SC, Hall JE. Psychosocial risks associated with multiple births resulting from assisted reproduction. *Fertil Steril* 2005;83:1422–8.
32. McWhinnie A. Euphoria or despair? Coping with multiple births from ART: what patients don't tell the clinics. *Hum Fertil (Camb)* 2000;3:20–5.
33. Glazebrook C, Sheard C, Cox S, Oates M, Ndukwe G. Parenting stress in first-time mothers of twins and triplets conceived after in vitro fertilization. *Fertil Steril* 2004;81:505–11.
34. Olivennes F, Golombok S, Ramogida C, Rust J. Behavioral and cognitive development as well as family functioning of twins conceived by assisted reproduction: findings from a large population study. *Fertil Steril* 2005;84:725–33.
35. Prevention of twin pregnancies after IVF/ICSI by single embryo transfer. ESHRE Campus Course Report. *Hum Reprod* 2001;16:790–800.
36. Adashi EY, Barri PN, Berkowitz R, Braude P, Bryan E, Carr J, et al. Infertility therapy-associated multiple pregnancies (births): an ongoing epidemic. *Reprod Biomed Online* 2003;7:515–42.
37. Buckett W, Tan SL. What is the most relevant standard of success in assisted reproduction? The importance of informed choice. *Hum Reprod* 2004;19:1043–5.
38. Dickey RP, Sartor BM, Pyrzak R. What is the most relevant standard of success in assisted reproduction?: no single outcome measure is satisfactory when evaluating success in assisted reproduction; both twin births and singleton births should be counted as successes. *Hum Reprod* 2004;19:783–7.
39. Min JK, Breheny SA, MacLachlan V, Healy DL. What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BESST endpoint for assisted reproduction. *Hum Reprod* 2004;19:3–7.
40. Olivennes F. Avoiding multiple pregnancies in ART. Double trouble: yes a twin pregnancy is an adverse outcome. *Hum Reprod* 2000;15:1663–5.
41. Bergh T, Ericson A, Hillensjo T, Nygren KG, Wennerholm UB. Deliveries and children born after in-vitro fertilisation in Sweden 1982–95: a retrospective cohort study. *Lancet* 1999;354:1579–85.
42. Kinzler WL, Ananth CV, Vintzileos AM. Medical and economic effects of twin gestations. *J Soc Gynecol Investig* 2000;7:321–7.
43. Reynolds MA, Schieve LA. Trends in embryo transfer practices and multiple gestation for IVF procedures in the USA, 1996–2002. *Hum Reprod* 2006;21:694–700.
44. Dickey RP, Taylor SN, Lu PY, Sartor BM, Storment JM, Rye PH, et al. Spontaneous reduction of multiple pregnancy: incidence and effect on outcome. *Am J Obstet Gynecol* 2002;186:77–83.
45. Friedman BE, Rosen MP, Shen S, Dobson AT, Shaline LK, Cedars MI. The effect of a vanishing twin on perinatal outcomes. *Fertil Steril* 2005;84:S1–S2.
46. Hvidtjorn D, Grove J, Schendel D, Vaeth M, Ernst E, Nielsen L et al. 'Vanishing embryo syndrome' in IVF/ICSI. *Hum Reprod* 2005;20:2550–1.
47. Pinborg A, Lidegaard O, la Cour FN, Nyboe Andersen A. Consequences of vanishing twins in IVF/ICSI pregnancies. *Hum Reprod* 2005;20:2821–9.
48. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. *N Engl J Med* 2002;346:731–7.
49. Wang YA, Sullivan EA, Black D, Dean J, Bryant J, Chapman M. Preterm birth and low birth weight after assisted reproductive technology-related pregnancy in Australia between 1996 and 2000. *Fertil Steril* 2005;83:1650–8.
50. Evans MI, Berkowitz RL, Wapner RJ, Carpenter RJ, Goldberg JD, Ayoub MA, et al. Improvement in outcomes of multifetal pregnancy reduction with increased experience. *Am J Obstet Gynecol* 2001;184:97–103.
51. Angel JL, Kalter CS, Morales WJ, Rasmussen C, Caron L. Aggressive perinatal care for high-order multiple gestations: Does good perinatal outcome justify aggressive assisted reproductive techniques? *Am J Obstet Gynecol* 1999;181:253–9.
52. Antsaklis AJ, Drakakis P, Vlazakis GP, Michalas S. Reduction of multifetal pregnancies to twins does not increase obstetric or perinatal risks. *Hum Reprod* 1999;14:1338–40.
53. Leondires MP, Ernst SD, Miller BT, Scott RT Jr. Triplets: outcomes of expectant management versus multifetal reduction for 127 pregnancies. *Am J Obstet Gynecol* 2000;183:454–9.
54. Bergh C, Moller A, Nilsson L, Wikland M. Obstetric outcome and psychological follow-up of pregnancies after embryo reduction. *Hum Reprod* 1999;14:2170–5.
55. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W. Canadian Task Force on the Periodic Health Exam. Ottawa: Canada Communication Group; 1994. p.xvii.
56. Schnorr JA, Doviak MJ, Muasher SJ, Jones HW Jr. Impact of a cryopreservation program on the multiple pregnancy rate associated with assisted reproductive technologies. *Fertil Steril* 2001;75:147–51.
57. Elsner CW, Tucker MJ, Sweitzer CL, Brockman WD, Morton PC, Wright G, et al. Multiple pregnancy rate and embryo number transferred during in vitro fertilization. *Am J Obstet Gynecol* 1997;177:350–5.
58. Ozturk O, Templeton A. In-vitro fertilisation and risk of multiple pregnancy. *Lancet* 2002;359:232.

59. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. *N Engl J Med* 1998;339:573-7.
60. Grochowski D, Wolczynski S, Kulikowski M, Kuczynski W, Szamatowicz M. Prevention of high-order multiple gestations in an in vitro fertilization program. *Gynecol Endocrinol* 1997;11:327-30.
61. Fujii S, Fukui A, Yamaguchi E, Sakamoto T, Sato S, Saito Y. Reducing multiple pregnancies by restricting the number of embryos transferred to two at the first embryo transfer attempt. *Hum Reprod* 1998;13:3550-4.
62. Devreker F, Emiliani S, Revelard P, Van den Bergh M, Govaerts I, Englert Y. Comparison of two elective transfer policies of two embryos to reduce multiple pregnancies without impairing pregnancy rates. *Hum Reprod* 1999;14:83-9.
63. Dean NL, Phillips SJ, Buckett WM, Biljan MM, Tan SL. Impact of reducing the number of embryos transferred from three to two in women under the age of 35 who produced three or more high-quality embryos. *Fertil Steril* 2000;74:820-3.
64. Nijs M, Geerts L, van Roosendaal E, Segal-Bertin G, Vanderzwalmen P, Schoysman R. Prevention of multiple pregnancies in an in vitro fertilization program. *Fertil Steril* 1993;59:1245-50.
65. Coetsier T, Dhont M. Avoiding multiple pregnancies in in-vitro fertilization: who's afraid of single embryo transfer? *Hum Reprod* 1998;13:2663-4.
66. Bhattacharya S, Templeton A. What is the most relevant standard of success in assisted reproduction? Redefining success in the context of elective single embryo transfer: evidence, intuition and financial reality. *Hum Reprod* 2004;19:1939-42.
67. Engmann L, Maconochie N, Tan SL, Bekir J. Trends in the incidence of births and multiple births and the factors that determine the probability of multiple birth after IVF treatment. *Hum Reprod* 2001;16:2598-605.
68. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. *Fertil Steril* 2000;73:1155-8.
69. Ludwig M, Schopper B, Al-Hasani S, Diedrich K. Clinical use of a pronuclear stage score following intracytoplasmic sperm injection: impact on pregnancy rates under the conditions of the German embryo protection law. *Hum Reprod* 2000;15:325-9.
70. Saldeen P, Sundstrom P. Nuclear status of four-cell preembryos predicts implantation potential in in vitro fertilization treatment cycles. *Fertil Steril* 2005;84:584-9.
71. Van Royen E, Mangelschots K, De Neubourg D, Valkenburg M, Van de Meerssche M, Ryckaert G, et al. Characterization of a top quality embryo, a step towards single-embryo transfer. *Hum Reprod* 1999;14:2345-9.
72. Hunault CC, Eijkemans MJ, Pieters MH, te Velde ER, Habbema JD, Fauser BC, et al. A prediction model for selecting patients undergoing in vitro fertilization for elective single embryo transfer. *Fertil Steril* 2002;77:725-32.
73. Peterson CM, Reading JC, Hatasaka HH, Parker JK, Udoff LC, Adashi EY, et al. Use of outcomes-based data in reducing high-order multiple pregnancies: the role of age, diagnosis, and embryo score. *Fertil Steril* 2004;81:1534-41.
74. Strandell A, Bergh C, Lundin K. Selection of patients suitable for one-embryo transfer may reduce the rate of multiple births by half without impairment of overall birth rates. *Hum Reprod* 2000;15:2520-5.
75. Blake D, Proctor M, Johnson N, Olive D, Blake D. Cleavage stage versus blastocyst stage embryo transfer in assisted conception. *Cochrane Database Syst Rev* 2005;CD002118.
76. Gardner DK, Schoolcraft WB, Wagley L, Schlenker T, Stevens J, Hesla J. A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. *Hum Reprod* 1998;13:3434-40.
77. Karaki RZ, Samarraie SS, Younis NA, Lahloub TM, Ibrahim MH. Blastocyst culture and transfer: a step toward improved in vitro fertilization outcome. *Fertil Steril* 2002;77:114-8.
78. Milki AA, Hinckley MD, Fisch JD, Dasig D, Behr B. Comparison of blastocyst transfer with day 3 embryo transfer in similar patient populations. *Fertil Steril* 2000;73:126-9.
79. Van der Auwera I, Debrock S, Spiessens C, Afschrift H, Bakelants E, Meuleman C et al. A prospective randomized study: day 2 versus day 5 embryo transfer. *Hum Reprod* 2002;17:1507-12.
80. Wilson M, Hartke K, Kiehl M, Rodgers J, Brabec C, Lyles R. Integration of blastocyst transfer for all patients. *Fertil Steril* 2002;77:693-6.
81. Wilson M, Hartke K, Kiehl M, Rodgers J, Brabec C, Lyles R. Transfer of blastocysts and morulae on day 5. *Fertil Steril* 2004;82:327-33.
82. Papanikolaou EG, Camus M, Kolibianakis EM, Van LL, Van SA, Devroey P. In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. *N Engl J Med* 2006;354:1139-46.
83. Vauthier-Brouzes D, Lefebvre G, Lesourd S, Gonzales J, Darbois Y. How many embryos should be transferred in in vitro fertilization? A prospective randomized study. *Fertil Steril* 1994;62:339-42.
84. Komori S, Kasumi H, Horiuchi I, Hamada Y, Suzuki C, Shigeta M, et al. Prevention of multiple pregnancies by restricting the number of transferred embryos: randomized control study. *Arch Gynecol Obstet* 2004;270:91-3.
85. Staessen C, Janssenswillen C, Van den AE, Devroey P, Van Steirteghem AC. Avoidance of triplet pregnancies by elective transfer of two good quality embryos. *Hum Reprod* 1993;8:1650-3.
86. Salha O, Dada T, Levett S, Allgar V, Sharma V. The influence of supernumerary embryos on the clinical outcome of IVF cycles. *J Assist Reprod Genet* 2000;17:335-43.
87. Ludwig M, Schopper B, Katalinic A, Sturm R, Al-Hasani S, Diedrich K. Experience with the elective transfer of two embryos under the conditions of the German embryo protection law: results of a retrospective data analysis of 2573 transfer cycles. *Hum Reprod* 2000;15:319-24.
88. Matson PL, Browne J, Deakin R, Bellinge B. The transfer of two embryos instead of three to reduce the risk of multiple pregnancy: a retrospective analysis. *J Assist Reprod Genet* 1999;16:1-5.
89. Tasdemir M, Tasdemir I, Kodama H, Fukuda J, Tanaka T. Two instead of three embryo transfer in in-vitro fertilization. *Hum Reprod* 1995;10:2155-8.
90. Staessen C, Nagy ZP, Liu J, Janssenswillen C, Camus M, Devroey P, et al. One year's experience with elective transfer of two good quality embryos in the human in-vitro fertilization and intracytoplasmic sperm injection programmes. *Hum Reprod* 1995;10:3305-12.
91. Gerris J, De Neubourg D, Mangelschots K, Van Royen E, Vercruyssen M, Barudy-Vasquez J, et al. Elective single day 3 embryo transfer halves the twinning rate without decrease in the ongoing pregnancy rate of an IVF/ICSI programme. *Hum Reprod* 2002;17:2626-31.
92. Schieve LA, Peterson HB, Meikle SF, Jeng G, Danel I, Burnett NM, et al. Live-birth rates and multiple-birth risk using in vitro fertilization. *JAMA* 1999;282:1832-8.
93. Gardner DK, Surrey E, Minjarez D, Leitz A, Stevens J, Schoolcraft WB. Single blastocyst transfer: a prospective randomized trial. *Fertil Steril* 2004;81:551-5.
94. Gerris J, De Neubourg D, Mangelschots K, Van Royen E, Van de Meerssche M, Valkenburg M. Prevention of twin pregnancy after in-vitro fertilization or intracytoplasmic sperm injection based on strict embryo criteria: a prospective randomized clinical trial. *Hum Reprod* 1999;14:2581-7.
95. Lukassen HG, Braat DD, Wetzels AM, Zielhuis GA, Adang EM, Scheenjes E et al. Two cycles with single embryo transfer versus one cycle with double embryo transfer: a randomized controlled trial. *Hum Reprod* 2005;20:702-8.
96. Martikainen H, Tiitinen A, Tomas C, Tapanainen J, Orava M, Tuomivaara L, et al. One versus two embryo transfer after IVF and ICSI: a randomized study. *Hum Reprod* 2001;16:1900-3.

97. Thurin A, Hausken J, Hillensjo T, Jablonowska B, Pinborg A, Strandell A, et al. Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. *N Engl J Med* 2004;351:2392-402.
98. van Montfoort AP, Fiddelers AA, Janssen JM, Derhaag JG, Dirksen CD, Dunselman GA, et al. In unselected patients, elective single embryo transfer prevents all multiples, but results in significantly lower pregnancy rates compared with double embryo transfer: a randomized controlled trial. *Hum Reprod* 2006;21:338-43.
99. Pandian Z, Templeton A, Serour G, Bhattacharya S. Number of embryos for transfer after IVF and ICSI: a Cochrane review. *Hum Reprod* 2005;20:2681-7.
100. Alikani M, Cekleniak NA, Walters E, Cohen J. Monozygotic twinning following assisted conception: an analysis of 81 consecutive cases. *Hum Reprod* 2003;18:1937-43.
101. Gerris JM. Single embryo transfer and IVF/ICSI outcome: a balanced appraisal. *Hum Reprod Update* 2005;11:105-21.
102. Vilksa S, Tiitinen A, Hyden-Granskog C, Hovatta O. Elective transfer of one embryo results in an acceptable pregnancy rate and eliminates the risk of multiple birth. *Hum Reprod* 1999;14:2392-5.
103. Catt J, Wood T, Henman M, Jansen R. Single embryo transfer in IVF to prevent multiple pregnancies. *Twin Res* 2003;6:536-9.
104. De Sutter P, Van der Elst J, Coetsier T, Dhont M. Single embryo transfer and multiple pregnancy rate reduction in IVF/ICSI: a 5-year appraisal. *Reprod Biomed Online* 2003;6:464-9.
105. Kovacs G, MacLachlan V, Rombauts L, Healy D, Howlett D. Replacement of one selected embryo is just as successful as two embryo transfer, without the risk of twin pregnancy. *Aust N Z J Obstet Gynaecol* 2003;43:369-71.
106. Soderstrom-Anttila V, Vilksa S, Makinen S, Foudila T, Suikkari AM. Elective single embryo transfer yields good delivery rates in oocyte donation. *Hum Reprod* 2003;18:1858-63.
107. Tiitinen A, Unkila-Kallio L, Halttunen M, Hyden-Granskog C. Impact of elective single embryo transfer on the twin pregnancy rate. *Hum Reprod* 2003;18:1449-53.
108. Gerris J, De Sutter P, De Neubourg D, Van Royen E, Van der Elst J, Mangelschots K, et al. A real-life prospective health economic study of elective single embryo transfer versus two-embryo transfer in first IVF/ICSI cycles. *Hum Reprod* 2004;19:917-23.
109. Martikainen H, Orava M, Lakkakorpi J, Tuomivaara L. Day 2 elective single embryo transfer in clinical practice: better outcome in ICSI cycles. *Hum Reprod* 2004;19:1364-6.
110. van Montfoort AP, Dumoulin JC, Land JA, Coonen E, Derhaag JG, Evers JL. Elective single embryo transfer (eSET) policy in the first three IVF/ICSI treatment cycles. *Hum Reprod* 2005;20:433-6.
111. Criniti A, Thyer A, Chow G, Lin P, Klein N, Soules M. Elective single blastocyst transfer reduces twin rates without compromising pregnancy rates. *Fertil Steril* 2005;84:1613-9.
112. Henman M, Catt JW, Wood T, Bowman MC, de Boer KA, Jansen RPS. Elective transfer of single fresh blastocysts and later transfer of cryostored blastocysts reduces the twin pregnancy rate and can improve the in vitro fertilization live birth rate in younger women. *Fertil Steril* 2005;84:1620-7.
113. Tiitinen A, Halttunen M, Harkki P, Vuoristo P, Hyden-Granskog C. Elective single embryo transfer: the value of cryopreservation. *Hum Reprod* 2001;16:1140-4.
114. Davis OK. Elective single-embryo transfer—has its time arrived? *N Engl J Med* 2004;351:2440-2.
115. Tiitinen A, Hyden-Granskog C, Gissler M. What is the most relevant standard of success in assisted reproduction? The value of cryopreservation on cumulative pregnancy rates per single oocyte retrieval should not be forgotten. *Hum Reprod* 2004;19:2439-41.
116. Gerris J, De Neubourg D, De Sutter P, Van Royen E, Mangelschots K, Verduyssen M. Cryopreservation as a tool to reduce multiple birth. *Reprod Biomed Online* 2003;7:286-94.
117. Hyden-Granskog C, Tiitinen A. Single embryo transfer in clinical practice. *Hum Fertil (Camb)* 2004;7:175-82.
118. Debrock S, Spiessens C, Meuleman C, Segal L, De Loecker P, Meeuwis L, et al. New Belgian legislation regarding the limitation of transferable embryos in in vitro fertilization cycles does not significantly influence the pregnancy rate but reduces the multiple pregnancy rate in a threefold way in the Leuven University Fertility Center. *Fertil Steril* 2005;83:1572-4.
119. De Neubourg D, Mangelschots K, Van Royen E, Verduyssen M, Ryckaert G, Valkenburg M, et al. Impact of patients' choice for single embryo transfer of a top quality embryo versus double embryo transfer in the first IVF/ICSI cycle. *Hum Reprod* 2002;17:2621-5.
120. Saldeen P, Sundstrom P. Would legislation imposing single embryo transfer be a feasible way to reduce the rate of multiple pregnancies after IVF treatment? *Hum Reprod* 2005;20:4-8.
121. Svendsen TO, Jones D, Butler L, Muasher SJ. The incidence of multiple gestations after in vitro fertilization is dependent on the number of embryos transferred and maternal age. *Fertil Steril* 1996;65:561-5.
122. Hu Y, Maxson WS, Hoffman DI, Ory SJ, Eager S, Dupre J, et al. Maximizing pregnancy rates and limiting higher-order multiple conceptions by determining the optimal number of embryos to transfer based on quality. *Fertil Steril* 1998;69:650-7.
123. Giannini P, Piscitelli C, Giallonardo A, Sbracia M, Morgia F, Torti M, et al. Number of embryos transferred and implantation. *Ann N Y Acad Sci* 2004;1034:278-83.
124. Milki AA, Hinckley MD, Westphal LM, Behr B. Elective single blastocyst transfer. *Fertil Steril* 2004;81:1697-8.
125. Adonakis G, Camus M, Joris H, Vandervorst M, Van Steirteghem A, Devroey P. The role of the number of replaced embryos on intracytoplasmic sperm injection outcome in women over the age of 40. *Hum Reprod* 1997;12:2542-5.
126. Azem F, Yaron Y, Amit A, Yovel I, Barak Y, Peyser MR, et al. Transfer of six or more embryos improves success rates in patients with repeated in vitro fertilization failures. *Fertil Steril* 1995;63:1043-6.
127. Licciardi F, Berkeley AS, Krey L, Grifo J, Noyes N. A two- versus three-embryo transfer: the oocyte donation model. *Fertil Steril* 2001;75:510-3.
128. Ryan GL, Zhang SH, Dokras A, Syrop CH, Van Voorhis BJ. The desire of infertile patients for multiple births. *Fertil Steril* 2004;81:500-4.
129. Pinborg A, Loft A, Schmidt L, Nyboe Andersen A. Attitudes of IVF/ICSI-twin mothers towards twins and single embryo transfer. *Hum Reprod* 2003;18:621-7.
130. Goldfarb J, Kinzer DJ, Boyle M, Kurit D. Attitudes of in vitro fertilization and intrauterine insemination couples toward multiple gestation pregnancy and multifetal pregnancy reduction. *Fertil Steril* 1996;65:815-20.
131. Grobman WA, Milad MP, Stout J, Klock SC. Patient perceptions of multiple gestations: an assessment of knowledge and risk aversion. *Am J Obstet Gynecol* 2001;185:920-4.
132. Murray S, Shetty A, Rattray A, Taylor V, Bhattacharya S. A randomized comparison of alternative methods of information provision on the acceptability of elective single embryo transfer. *Hum Reprod* 2004;19:911-6.
133. Porter M, Bhattacharya S. Investigation of staff and patients' opinions of a proposed trial of elective single embryo transfer. *Hum Reprod* 2005;20:2523-30.
134. Blennborn M, Nilsson S, Hillervik C, Hellberg D. The couple's decision-making in IVF: one or two embryos at transfer? *Hum Reprod* 2005;20:1292-7.

135. Chervenak FA, McCullough LB, Rosenwaks Z. Ethical dimensions of the number of embryos to be transferred in in vitro fertilization. *J Assist Reprod Genet* 2001;18:583–7.
136. Jain T, Harlow BL, Hornstein MD. Insurance coverage and outcomes of in vitro fertilization. *N Engl J Med* 2002;347:661–6.
137. Reynolds MA, Schieve LA, Jeng G, Peterson HB. Does insurance coverage decrease the risk for multiple births associated with assisted reproductive technology? *Fertil Steril* 2003;80:16–23.
138. Gordts S, Campo R, Puttemans P, Brosens I, Valkenburg M, Norre J, et al. Belgian legislation and the effect of elective single embryo transfer on IVF outcome. *Reprod Biomed Online* 2005;10:436–41.
139. Ombet W, De Sutter P, Van der Elst J, Martens G. Multiple gestation and infertility treatment: registration, reflection and reaction—the Belgian project. *Hum Reprod Update* 2005;11:3–14.
140. Callahan TL, Hall JE, Ettner SL, Christiansen CL, Greene MF, Crowley WF Jr. The economic impact of multiple-gestation pregnancies and the contribution of assisted-reproduction techniques to their incidence. *N Engl J Med* 1994;331:244–9.
141. Kjellberg AT, Carlsson P, Bergh C. Randomized single versus double embryo transfer: obstetric and paediatric outcome and a cost-effectiveness analysis. *Hum Reprod* 2006;21:210–6.
142. De Sutter P, Gerris J, Dhont M. A health-economic decision-analytic model comparing double with single embryo transfer in IVF/ICSI. *Hum Reprod* 2002;17:2891–6.
143. Bolton P, Yamashita Y, Farquhar CM. Role of fertility treatments in multiple pregnancy at National Women's Hospital from 1996 to 2001. *Aust N Z J Obstet Gynaecol* 2003;43:364–8.
144. Dmowski WP, Pry M, Ding J, Rana N. Cycle-specific and cumulative fecundity in patients with endometriosis who are undergoing controlled ovarian hyperstimulation-intrauterine insemination or in vitro fertilization-embryo transfer. *Fertil Steril* 2002;78:750–6.
145. Dickey RP. It has really been 15 years of inaction on high-order multiple pregnancies due to ovulation induction. *Fertil Steril* 2003;79:28–9.
146. Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Risk factors for high-order multiple pregnancy and multiple birth after controlled ovarian hyperstimulation: results of 4,062 intrauterine insemination cycles. *Fertil Steril* 2005;83:671–83.
147. Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. *N Engl J Med* 2000;343:2–7.